Natera
Invitae Sues Natera Over Alleged Infringement of Sequence Assembly Patents
Invitae is seeking damages and other costs, as well as an order enjoining Natera from infringing its '308 and '863 patents, which were granted last month.
Natera Accused of Unfair, Deceptive Billing Practices Related to NIPT Services in New Lawsuit
The plaintiff, a woman who'd used the company's Panorama test during a pregnancy, is asking the court to certify her case a class action.
The company has signed a deal with Aarhus University that gives it access to a 40,000-sample biobank of patients who were screened for colorectal cancer.
Natera Q3 Revenues Grow 61 Percent
The company reported $158.1 million in total revenues for the quarter and said product revenues rose 62 percent from the prior-year quarter.
BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium
The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.
Aug 5, 2021
Natera Q2 Revenues Grow 64 Percent
Jul 21, 2021
Natera Prices, Upsizes Public Stock Offering
Jul 13, 2021
Natera Inks Distribution Deal With TomaLab for Italy
May 6, 2021
Natera Q1 Revenues Grow 62 Percent
May 5, 2021
Personalis Q1 Revenues Grow 9 Percent
Feb 26, 2021
Feb 25, 2021